Standard Dosing Schedules for Nivolumab
Nivolumab (Opdivo) is typically administered intravenously every 2 weeks or every 4 weeks, depending on the cancer type, patient weight, and combination therapy. Doses range from 240 mg to 480 mg per infusion, with flat dosing (not weight-based) common in recent approvals.[1]
- For monotherapy in melanoma, NSCLC, or renal cell carcinoma: 240 mg every 2 weeks or 480 mg every 4 weeks.
- In combination (e.g., with ipilimumab for melanoma): Often 240 mg every 2 weeks initially, then adjusted.
- For MSI-H/dMMR cancers: 240 mg every 2 weeks or 360 mg every 3 weeks.
Treatment continues until disease progression, unacceptable toxicity, or up to 2 years in some responsive cases.[1]
How Dosing Varies by Cancer Type
Schedules differ by indication:
- Melanoma: 240 mg IV every 2 weeks or 480 mg every 4 weeks (monotherapy); with ipilimumab, every 3 weeks for 4 doses, then every 2 weeks.
- NSCLC: 360 mg every 3 weeks (with platinum-doublet chemo) or 240 mg every 2 weeks post-platinum therapy.
- Hodgkin lymphoma: 240 mg every 2 weeks.
- Head and neck squamous cell carcinoma: 240 mg every 2 weeks with chemo-radiation.
Pediatric dosing (for some solid tumors) is weight-based at 3 mg/kg every 2 weeks.[1]
Why Frequency Changed Over Time
Early approvals used weight-based dosing (3 mg/kg every 2 weeks), but FDA updates since 2017 shifted to fixed doses (240/360/480 mg) every 2-4 weeks for convenience and similar efficacy. This reduces calculation errors and infusion time (30 minutes).[1][2]
What Happens If a Dose Is Missed or Delayed
Administer the next dose as soon as possible, then resume the original schedule. No dose adjustment needed for delays under 3 months in most cases, but monitor for progression.[1]
Common Patient Concerns on Administration
Infusions take 30 minutes; premedication isn't required. Frequency can cause fatigue from travel/clinic visits—every 4 weeks eases this versus every 2. Side effects like immune-related issues may prompt schedule holds.[3]
[1]: Opdivo Prescribing Information (Bristol Myers Squibb)
[2]: FDA Label Updates for Nivolumab
[3]: NCCN Guidelines: Nivolumab Dosing